BLOOD Centers Act
- Sponsor
- Rep. Wied, Tony [R-WI-8]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Oct 17, 2025
Bottom line
The BLOOD Centers Act aims to streamline the FDA approval process for established blood centers to expand their apheresis collection capabilities, potentially increasing the national blood supply.
What it actually does
This bill directs the Secretary of Health and Human Services, through the Commissioner of Food and Drugs, to establish an expedited approval process for blood centers seeking to add an apheresis collection device to an existing biologics license application (BLA) at a new, previously unlicensed location. The process mandates approval within 30 days unless specific safety concerns or systemic failures are identified, and applies to blood centers with multiple existing licensed sites or those in good standing with an accredited organization.
Proponents argue
Supporters argue that this bill will significantly reduce administrative delays and burdens for reputable blood centers, allowing them to more quickly establish new collection sites and expand their capacity to collect lifesaving blood products. They contend that the current approval process can be unnecessarily slow, hindering efforts to maintain an adequate blood supply. The bill includes safeguards to ensure that safety, purity, and potency standards are maintained, making it a balanced approach to efficiency and public health.
Opponents contend
Critics might express concern that while the goal of increasing blood supply is laudable, an expedited 30-day approval process could potentially compromise the thoroughness of FDA's review, even with the stated exceptions. They might argue that any reduction in oversight, however slight, could introduce risks to the safety of blood products or donor welfare, and that the existing review process, while slower, is designed to ensure maximum safety.
The bill is very short and easy to read, making it accessible for anyone to understand its core provisions quickly.
Section 2(a)
Establishment of Expedited Approval Process
This provision mandates that the Secretary of Health and Human Services, through the FDA, create a faster way for blood centers to get approval. This expedited process is specifically for when a blood center wants to add a new apheresis collection device (used to collect specific blood components like plasma or platelets) at a location that isn't already covered by their existing license. The goal is to speed up the expansion of blood collection capabilities.
Supporters argue
Supporters argue this provision is crucial for addressing potential blood shortages by enabling blood centers to expand their collection infrastructure more efficiently. They believe it removes unnecessary bureaucratic hurdles without sacrificing safety, as it focuses on established centers adding devices to existing licenses.
Critics contend
Some might argue that any expedited process, even with safeguards, could strain FDA resources or lead to less thorough reviews than the standard process, potentially increasing risks. They might contend that the current review, while slower, is essential for maintaining the highest safety standards.
Tradeoffs
This provision balances the desire for increased efficiency in blood collection and expansion of the blood supply against the need for rigorous regulatory oversight to ensure the safety and purity of blood products.
Section 2(b)
30-Day Approval Deadline with Safety Exceptions
This part of the bill sets a strict 30-day deadline for the FDA to approve a supplemental application under the new expedited process. However, it includes critical exceptions: the FDA can deny or delay approval if there's a specific safety concern at the proposed new location, or if the blood center has a history of systemic failures to meet safety standards at its other licensed locations. This ensures that speed does not override fundamental safety requirements.
Section 2(c)
Eligibility Criteria for Expedited Procedure
This section defines which blood centers are eligible to use the expedited approval process. To qualify, a blood center must already hold a biologics license for at least one site. Additionally, it must either have three or more FDA-registered locations under that existing license, or be accredited and in good standing by an organization whose standards meet or exceed FDA's requirements for blood collections. This ensures that only established and demonstrably compliant centers can utilize the faster pathway.
Allows blood centers accredited by an organization with standards meeting or exceeding FDA requirements to qualify for the expedited process.
Section 2(c)(2)(B)
Why it matters:This is standard legislative practice for defining alternative compliance pathways, ensuring flexibility while maintaining regulatory rigor.
Case for: This provides an alternative pathway for qualification, recognizing the robust oversight provided by reputable accreditation bodies and potentially reducing redundant FDA review for already well-regulated entities.
Case against: The phrase 'meet or exceed, as determined by the Secretary, all applicable regulatory requirements' introduces a subjective element that could lead to delays or inconsistencies in determining which accreditation bodies qualify.
Estimated impact: Potentially broadens the pool of eligible blood centers beyond those with extensive FDA-registered sites, particularly benefiting those that invest in high-standard third-party accreditation.